RegiSCAR

ReferencesCompany Profile

Results

RegiSCAR ist just the last in a row of multinational studies on the topicof Severe Cutaneous Adverse Drug Reactions. Many collaborators and active participants have - over the years - published a large number of papers addressing this topic from different angles. The following list is just an unstructured compilations of some ofthese publications.

List of publications

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6

Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs.N Engl J Med. 1994;331:1272-85.

Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, Correia O, Shapiro S, Kaufman DW. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995;48:1099-108 

Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-7.

Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 1999;353:2190-4.

Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol. 2001 Mar;28(3):113-9.

Viboud C, Boëlle PY, Kelly J, Auquier A, Schlingmann J, Roujeau JC, Flahault A. Comparison of the statistical efficiency of case-crossover and case-control designs: application to severe cutaneous adverse reactions. J Clin Epidemiol. 2001;54:1218-27.

Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC; EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001;15:1843-8.

Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-24

Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30:2234-40.

Mockenhaupt M, Roujeau JC. EMPACT syndrome. J Dtsch Dermatol Ges. 2005;3:569-70.

Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC; RegiSCAR Group. A marker for

Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006;6:265-8.

Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-11.

Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989-96.

Valeyrie-Allanore L, Poulalhon N, Fagot JP Sekula P, Davidovici B, Sidoroff A, Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol. 2008 ;87:300-3.

Lonjou C, Borot N, Sekula P. Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99-107.

Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.

Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.

Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.

Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, Martin E, Kaufman DW, Maison P. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123:e297-304.

Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol (JEADV) 2009; 23 (6): 702-703.

Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;  

11(3): 349-356.

Halevy S, Kardaun SH, Davidovici B, Wechsler J; EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010;163:1245-52

Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146 (12): 1373-1379.

Sassolas B, Haddad C, Mockenhaupt M Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H.. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis. Clin Pharmacol Ther. 2010;88:60-8

Sekula P, Caputo A, Dunant A Roujeau JC, Mockenhaupt M, Sidoroff A, Schumacher MAn application of propensity score methods to estimate the treatment effect of corticosteroids in patients with severe cutaneous adverse reactions. Pharmacoepidemiol Drug Saf. 2010;19:10-8

de Araujo E, Dessirier V, Laprée G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN, Bagot M, Bensussan A, Mockenhaupt M, Roujeau JC, Tsapis A. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011 Feb;20(2):107-12

Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011 Mar;127(3 Suppl):S60-6.

Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, Naldi L, Schumacher M, Mockenhaupt M. Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study. J Burn Care Res. 2011 March/April;32(2):237-245.

Kelly JP, Kaufman DW, Dunant A, Mockenhaupt M, Roujeau JC. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol. 2011 Jun;64(6):1193-4.

Genin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, Sekula P, Hovnanian A, Mockenhaupt M. Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe. Orphanet J Rare Dis. 2011 Jul 29;6:52

Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, Bensussan A, Roujeau JC. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy. 2012;42:248-54.

Roujeau JC. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients  

selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012 Sep;167(3):555-62.

Lipowicz S, Sekula P, Ingen-Housz-Oro S, Liss Y, Sassolas B, Dunant A, Roujeau JC, Mockenhaupt M. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013 Apr;168(4):726-32

Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013 May;133(5):1197-204.

Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, Barker JN, Capon F, Creamer D, Roujeau JC, Sekula P, Simpson MA, Trembath RC, Mockenhaupt M, Smith CH. Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis J Invest Dermatol. 2013 Jul;133(7):1904-7.

Haddad C, Sidoroff A, Kardaun SH, Mockenhaupt M, Creamer D, Dunant A, Roujeau JC. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk? Drug Saf. 2013 Aug;36(8):681-6. 

Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY.Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: A retrospective cohort study in Taiwan. J Am Acad Dermatol (JAAD) 2013; 68 (3): 459-465.

Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M, Roujeau JC; The RegiSCAR study group. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013 Nov; 169(5): 1071-80.

Chen YC, Chang CY, Cho YT, Chiu HC, Chu CY.Reply to "Utilizing a diagnostic score when reporting the long-term sequelae of the drug reaction with eosinophilia and systemic symptoms". J Am Acad Dermatol (JAAD) J Am Acad Dermatol (JAAD) 2013; 69 (6): 1060-2

Komorowski L, Mockenhaupt M, Sekula P, Roujeau JC, Probst C, Teegen B, Li W, Stöcker W, Zillikens D. Lack of a Specific Humoral Autoreactivity in Sera From Patients With Early Erythema Exsudativum Multiforme Majus. J Invest Dermatol. 2013 Dec;133(12):2799-802.

Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, Chu CY. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol (JAAD) 2014; 70 (3): 539-48

Doerken S, Mockenhaupt M, Schumacher M, Sekula P. Assessment of the "case-chaos" design as an adjunct to the case-control design. Am J Epidemiol 2014; 179(6):775-780 doi: 10.1093/aje/kwt310

Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, Tsai SH, Wu TL, Bellón T, Tamouza R, Fortier C, Toubert A, Charron D, Hovnanian A, Wolkenstein P, Chung WH, Mockenhaupt M, Roujeau JC. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14(3):281-288. doi: 10.1038/tpj.2013.40

Hussain S, Berki DM, Choon SE, Burden AD, Allen MA, Arostegui J, Chaves A, Duckworth M, Irvine AD, Mockenhaupt M, Navarini AA, Seyger M, Soler-Palacin P, Prins C, Valeyrie-Allanore L, Vincente MA, Trembath R, Smith C, Barker J, Capon F. IL36RN mutations define a severe auto-inflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 2015; 135(4):1067-1070.e9. doi: 10.1016/j.jaci.2014.09.043

Chen YC, Chiang HH, Cho YT, Chang CY, Chen KL, Yang CW,Lee YH,Chu CY.Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions—a prospective comparative study. Allergy 2015; 70 (5): 568-75

Lin IC, Yang HC,Strong C, Yang CW, Cho YT, Chen KL,Chu CY. Liver injury in drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical study of 72 cases. J Am Acad Dermatol (JAAD) 2015; 72 (6): 984-91

Doerken S, Mockenhaupt M, Roujeau JC, Naldi L, Schumacher M, Sekula P. The case-crossover design via penalized regression. BMC Med Res Methodol 2016; 16(1):103. doi: 10.1186/s12874-016-0197-0

Bellón T, Lerma V, González-Valle O, González Herrada C, de Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.Br J Dermatol. 2016 Mar;174(3):621-4. doi: 10.1111/bjd.14201. Epub 2015 Dec 30. PMID: 26412570

Bellón T, Ramírez E, Borobia AM, Lerma V, Moreno-Hidalgo MA, Laosa O, Aramburu JA, González-Herrada C, de Abajo FJ. The HLA-B*15:02 allele in a Spanish Romani patient with carbamazepine-induced Stevens-Johnson syndrome.Pharmacogenomics. 2016 Apr;17(6):541-5. doi: 10.2217/pgs.16.10. Epub 2016 Mar 29. PMID: 27020614

Yang CW, Cho YT, Chen KL, Chen YC, Song HL,Chu CY. Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol (Stockh)  

2016; 96 (4): 525-9.

Chu CY. Autoantibodies against plakin family insevere drug eruptions — Does it matter? Br J Dermatol 2016; 175 (5): 866-867

Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, Irvine AD, Képíró L, Mockenhaupt M, Oon HH, Pinner J, Ranki A, Seyger MM, Soler-Palacin P, Storan ER, Tan ES, Valeyrie-Allanore L, Young HS, Trembath RC, Choon SE, Szell M, Bata-Csorgo Z, Smith CH, Di Meglio P, Barker JN, Capon F. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol 2016; 136(11):2251-2259 doi: 10.1016/j.jid.2016.06.618

Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castañer JL, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Cachafeiro L, González-Herrada C, González O, Aramburu JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in theSpanish population.Pharmacol Res. 2017 Jan;115:168-178. doi: 10.1016/j.phrs.2016.11.027. PMID: 27888155

González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma V, González O, Lorente JA, Rodríguez-Miguel A, González-Ramos J, Roustan G, Ramírez E, Bellón T, de Abajo FJ; PIELenRed Therapeutic Management Working Group. Cyclosporine use in Epidermal Necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. 2017;137:2092-2100.

Paulmann M, Mockenhaupt M. Unfreiwillige Reexposition: Generalisiertes bullöses fixes Arz-neiexanthem bei 2 älteren Patientinnen. Hautarzt 2017; 68:59–63. doi: 10.1007/s00105-016-38 50-y

Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol 2017; 153(6):514-522. doi: 10.1001/jamadermatol.2016.5668

Su SC, Mockenhaupt M, Wolkenstein P,Dunant A, Le Gouvello, Chen SB,Chosidow O, Valeyrie-Allanore L, Bellon-Heredia T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol 2017; 137(5):1065-1073. doi: 10.1016/j.jid.2016.11.034

Haddad C, Chosidow O, Valeyrie-Allanore L, Ghaleh B, Legrand T, Mockenhaupt M,

Barau C, Khoudour N, Sekula P, Wolkenstein P, Hulin A. Are Idiopathic Stevens-Johnson syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? Example of Phenylbutazone. J Invest Dermatol 2017; 137(5):1179-1181. doi: 10.1016/j.jid.2016.11.041

Paulmann M, Mockenhaupt M. Unfreiwillige Reexposition: Generalisiertes bullöses fixes Arzneiexanthem bei 2 älteren Patientinnen. Hautarzt 2017; 68:59–63. doi: 10.1007/s00105-016-3850-y

Elsner P, Mockenhaupt M. Generalized bullous fixed drug eruption following metamizole (re-) exposure: a medical error-analytic case study. Acta Derm Venereol 2018; 98: 376-377. doi: 10.2340/00015555-2840

Hsu SH,Yang CW, Hsieh YC, Cho YT, Liao JY, Liang CW, Cheng YP, Chu CY. Fever, eosinophilia, and abnormal liver function are early signs suggestive of DRESS: a comparative study between DRESS and MPE. Dermatologica Sinica2018; 36 (1): 25-29.

Weins AB, Scharfetter-Kochanek K, Weiss T, Brockow K, Biedermann T, Psotta-Schachtner C, Mockenhaupt M, Weiss JM. Is neutrophilic desquamative erythroderma a form of acute generalized exanthematous pustulosis? J Eur Acad Dermatol Venereol 2018; 32(6):e230-e232. doi:10.1111/jdv14751

Roujeau JC, Dunant A, Mockenhaupt M. Epidermal necrolysis, ocular complications, and „cold medicines“. J Allergy Clin Immunol Pract 2018; 6:703-704. doi: 10.1016/j.jaip.2017.10.033

Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O, González-Herrada C, Ramírez E, Bellón T, de Abajo FJ. Active surveillance of severe cutaneous adverse reactions: A case-population approach using a registry and a health care database. Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):1042-1050. doi: 10.1002/pds.4622.. PMID: 30051945

Cabañas R, Calderón O, Ramírez E, Fiandor A, Caballero T, Heredia R, Herranz P, Madero R, Quirce S, Bellón T. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy. 2018;48: 325-333.

Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O, González-Herrada C, Ramírez E, Bellón T, de Abajo FJ. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol. 2019 Feb;75(2):237-246. doi: 10.1007/s00228-018-2569-3. PMID: 30298362

Lin YT, Tsai SW, Yang CW, Tseng YH, Chu CY. Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer 2019 March; 129:110-111.

Mockenhaupt M, Wang CW, Hung SI, Sekula P, Schmidt AH, Pan RY, Chen CB, Dunant A, Le Gouvello S, Schumacher M, Valeyrie-Allanore L, Bellón T, Kardaun S, Jan YS, Chung WH, Roujeau JC. HLA‐B*57:01 confers genetic susceptibility to carbamazepine induced SJS/TEN in Europeans. Allergy 2019; 00:1-4. doi: 10.1111/all.13821

Mockenhaupt M. 25/w mit rasch progredientem Exanthem mit Blasenbildung und Schleimhautbeteiligung: Vorbereitung auf die Facharztprüfung: Folge54. Hautarzt 2019; 70(Suppl1):103-107. doi: 10.1007/s00105-019-4369-9

Brockow K, Ardern‐Jones M, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, Spiewak R, Torres MJ, Mortz CG. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy 2019; (1):14-27. doi: 10.1111/all.13562 

Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Schwere bullöse Exantheme unter Therapie mit Checkpoint‐Inhibitoren – zumeist schwere bullöse lichenoide Arzneimittelexantheme. Dtsch Dermatol Ges 2019; 9: 943-949 https://doi.org/ 10.1111/ddg.13876_g

Cho YT, Chu CY. Comment on "Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms". J Am Acad Dermatol. 2019 Jun;80(6):e181.

Reschke R, Mockenhaupt M, Simon JC, Ziemer M. Severe bullous skin eruptions on checkpoint inhibitor therapy – in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges 2019; English online version https://doi.org/ 10.1111/ddg.13876

Naegele D, Sekula P, Paulmann M, Mockenhaupt M. Incidence of Epidermal Necrolysis: Results of the German Registry. J Invest Dermatol 2020; 140(12):2525-2527. doi: 10.1016/j.jid.2020.03.968

Vergnano M, Mockenhaupt M, Benzian-Olsson N, Paulmann M, Grys K, Mahil SK, Chaloner C, Barbosa IA, August S, Burden AD, Choon SE, Cooper H, Navarini AA, Reynolds NJ, Wahie S, Warren RB, Wright A; APRICOT and PLUM study team, Hüffmeier U, Baum P, Visvanathan S, Barker JN, Smith CH, Capon F. Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. Am J Hum Genet 2020; 107(3):539-543

doi: 10.1016/j.ajhg.2020.06.020

Schauer F, Ishii N, Mockenhaupt M, Bruckner-Tuderman L, Hashimoto T, Kiritsi D. Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option. Front Immunol 2020; 10:3116

doi: 10.3389/fimmu.2019.03116

Bellón T, Rodríguez-Martín S, Cabañas R, Ramírez E, Lerma V, González-Herrada C, González O, Sendagorta E, Fiandor A, de Abajo FJ; PIELenRed study group. Assessment of drug causality in Stevens-Johnson syndrome/toxic epidermal necrolysis: Concordance between lymphocyte transformation test and ALDEN. Allergy. 2020 Apr;75(4):956-959. doi: 10.1111/all.14062. PMID: 31557316.

Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, Doña I, Fernández J, Garcia-Nunez I, García-Samaniego J, Lopez-Rico R, Marín-Serrano E, Mérida C, Moya M, Ortega-Rodríguez NR, Rivas Becerra B, Rojas-Perez-Ezquerra P, Sánchez-González MJ, Vega-Cabrera C, Vila-Albelda C, Bellón T. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-253. doi: 10.18176/jiaci.0480. PMID: 31932268.

Balas A, Ramírez E, Trigo E, Cabañas R, Fiandor A, Arsuaga M, Lerma V, Sanz B, Vicario JL, Herranz P, de Abajo F, Bellón T. HLA-A*68, -A*11:01, and –A*29:02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)/DRESS. J Allergy Clin Immunol Pract. 2020; 8: 3198-3200

Cho YT, Yang CW, Chen YC,Chu CY. Comment on "Viral reactivation in hospitalized DRESS patients: A retrospective study from a tertiary medical center in the United States". J Am Acad Dermatol. 2020 Sep; 83(3): e209-e210.

Lin YT, Yang JC,Chu CY. Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma.Lung Cancer. 2020 Oct; 148: 177-178.

Yang CW, Cho YT, Hsieh YC, Hsu SH, Chen KL, Chu CY. IP-10/CXCR3 axis is associated with HHV-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. Br J Dermatol 2020Nov;183(5):909-919.

Chen CB, Chen YE, Chu MT, Wang CW, Hui RC, Lu CW, Hsiao YP, Chu CY, Chang MM, Cheung CM, Cheng CY, Wang YW, Lin YJ, Chang CJ, Hung SI, Chung WH; Taiwan Severe Cutaneous Adverse Reaction Consortium. The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. J Eur Acad Dermatol Venereol 2021 Mar;35(3):712-720.

Review articles

Chen YC, Cho YT, Chang CY, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): A drug-induced hypersensitivity syndrome with variable clinical features. Dermatologica Sinica 2013; 31 (4): 196-204.

Mockenhaupt M. Schwere arzneimittelinduzierte Hautreaktionen: Stevens-Johnson-Syndrom und Toxisch epidermale Nekrolyse. Der Hautarzt 2014; 65(5):415-423

doi: 10.1007/s00105-013-2694-y

Roujeau JC, Haddad C, Paulmann M, Mockenhaupt M. Management of Nonimmediate Hypersensitivity Reactions to Drugs. Immunol Allergy Clin North Am 2014; 34(3):473-487

doi: 10.1016/j.iac.2014.04.012

Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg 2014; 33(1):10-16

doi: 10.12788/j.sder.0058

Stern RS, Mockenhaupt M. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact. Curr Immunol Rev 2014; 10(1):4-6

doi: 10.2174/1573395510666140606220615

Brockow K, Przybilla B, Aberer W, Bircher AJ, Brehler R, Dickel H, Fuchs T, Jakob T, Lange L, Pfützner W, Mockenhaupt M, Ott H, Pfaar O, Ring J, Sachs B, Sitter H, Trautmann A, Treudler R, Wedi B, Worm M, Wurpts G, Zuberbier T, Merk HF. Leitlinie Allergologische Diagnotik von Überempfindlichkeitsreaktionen auf Arzneimittel. Allergo J Int 2015; 24(3):94-105

doi: 10.1007/s40629-015-0052-6

Paulmann M, Mockenhaupt M. Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diag-nostik, Ätiologie und Therapie. J Dtsch Dermatol Ges 2015; 13(7):625-645

doi: 10.1111/ddg.130_12747

Yang CW, Chen YC, Cho YT, Chu CY.The role of viral reactivation in drug reaction with eosinophilia and systemic symptoms and other cutaneous adverse drug reactions (cADRs). Curr Dermatol Rep 2016; 5 (1): 5-11.

Paulmann M, Mockenhaupt M. Severe drug hypersensitivity reaction: Clinical pattern, diagnosis, etiology and therapeutic options. Curr Pharm Des 2016; 22:1-10

doi: 10.2174/1381612822666160928125152

Paulmann M, Mockenhaupt M. Fever in Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric cases: Laboratory work-up and antibiotic therapy. Ped Inf Dis J 2017; 36:513-515

doi: 10.1097/INF.0000000000001571

Cho YT, Chu CY. Treatments for severe cutaneous adverse reactions. J Immunol Res 2017; 1503709. doi:10.1155/2017/1503709

Mockenhaupt M. Schwere kutane Arzneimittelreaktionen im Kindesalter. Hautarzt2017; 68(10): 803-814

doi: 10.1007/s00105-017-4048-7

Mockenhaupt M. Akute, lebensbedrohliche Medikamentenreaktionen der Haut. Hautarzt 2018; 69:364-375

doi: 10.1007/s00105-018-4176-8

Mockenhaupt M, Paulmann M. Schwere Hautreaktionen auf neue Medikamente. Hautarzt 2018; 69:278-289

doi: 10.1007/s00105-018-4153-2

Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, Spiewak R, Torres MJ, Mortz CG. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy 2018; 00:1-14

doi: 10.1111/all.13562

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MB, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ. Special Article: SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. J Allergy Clin Immunol Pract 2018; 6(1):38-69

doi: 10.1016/j.jaip.2017.11.023

Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS, Chung WH, Lehloenya R, Mockenhaupt M, Peter J, Pirmohamed M, Roujeau JC, Shear NH, Tanno LT, Trubiano J, Valluzzi R, Barbaud A. Controversies in drug allergy: Testing for delayed reactions. J Allergy Clin Immunol 2019; 143:66-73

doi: 10.1016/j.jaci.2018.10.030

Ardern-Jones M, Mockenhaupt M. Making a diagnosis in severe cutaneous drug reactions. Curr Opin Allergy Clin Immunol 2019; 19:283-293

doi: 10.1097/aci.0000000000000546

Paulmann M, Mockenhaupt M. Schwere Hautreaktionen: klinisches Bild, Epidemiologie, Ätiologie, Pathogenese und Therapie. Allergo J Int 2019; 28:311-326

Paulmann M, Mockenhaupt M. Severe skin reactions: clinical picture, epidemiology,

etiology, pathogenesis, and treatment. Allergo J Int 2019; (English online version)

doi: 10.1007/s40629-019-00111-8

Chang WC, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, Bellón T, Biala AK, Bouchard C, Cavalleri GL, Chapman N, Chodosh J, Choi HK, Cibotti RR, Divito SJ, Dewar K, Dehaeck U, Etminan M, Forbes D, Fuchs E, Goldman JL, Holmes 4th JH, Hope EA, Hung SI, Hsieh CL, Iovieno A, Jagdeo J, Kim MK, Koelle DM, Lacouture ME, Le Pallec S, Lehloenya RJ, Lim R, Lowe A, McCawley J, McCawley J, Micheletti RG, Mockenhaupt M, Niemeyer K, Norcross MA, Oboh D, Olteanu C, Pasieka HB, Peter J, Pirmohamed M, Rieder M, Saeed HN, Shear NH, Shieh C, Straus S, Sukasem C, Sung C, Trubiano JA, Tsou SY, Ueta M, Volpi S, Wan C, Wang H, Wang ZQ, Weintraub J, Whale C, Wheatley LM, Whyte-Croasdaile S, Williams KB, Wright G, Yeung SN, Zhou L, Chung WH, Phillips EJ, Carleton BC. SJS/TEN 2019: From science to translation. J Dermatol Sci 2020; 98(1):2-12

doi: 10.1016/j.jdermsci.2020.02.003

Bellón T. Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. Drug Saf. 2019 Aug;42(8):973-992. doi: 10.1007/s40264-019-00825-2. PMID: 31020549 Review.

Mockenhaupt M. Bullous Drug Reactions. Acta Derm Venerol 2020; 100:adv00057

doi: 10.2340/00015555-3408

Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema exsudativum multiforme, Stevens-Johnson-Syndrom/toxische epidermale Nekrolyse – Diagnostik undTherapie. J Dtsch Dermatol Ges 2020; 18(6):547-553

Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. J Dtsch Dermatol Ges. 2020; English online version

doi: 10.1111/ddg.14118

Chu CY. Drug Eruptions: A great imitators. Clin Dermatol 2020 Mar-Apr; 38(2): 193-207.

Brockow K, Ardern‐Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, Spiewak R, Torres MJ, Mortz CG. EAACI-Positionspapier zur Klassifizierung von kutanen Manifestationen einer Arzneimittelüberempfindlichkeit. Allergologie 2020; 43(08):301-324

doi: 10.5414/ALX02125

Book chapters

Samel AD, Chia-Yu Chu. Drug Eruptions. UpToDate, 2013-.

Mockenhaupt M, Ziemer M. Erythema multiforme majus, Stevens-Johnson syndrome, Toxic epidermal necrolysis and Graft-versus-Host disease. In Kirtschig G, Cooper S (Eds) Gyneco-logic Dermatology, Chapt. 18, JP Medical Printers Ltd., London, pp 79-88 (2015)

Mockenhaupt M. Schwere blasenbildende Hautreaktionen. In Lehnhardt M. et al (Eds) Ver-brennungschirurgie, Chapt. 36, Springer-Verlag Berlin Heidelberg; pp 390-401 (2016)

doi: 10.1007/978-3-642-54444-6_36

Mockenhaupt M. Das Dokumentationszentrum schwerer Hautreaktionen (dZh). In Lehnhardt M. et al (Eds) Verbrennungschirurgie, Chapt. 37, Springer-Verlag Berlin Heidelberg, pp 403-416 (2016)

doi: 10.1007/978-3-642-54444-6_37

Chia-Yu Chu. Drug Eruptions. In: Sauer’s Manual of Skin Diseases. Chapter 9, pp 95-121, 2017.Philadelphia, USA.

Chia-Yu Chu. Acute Generalized Exanthematous Pustulosis (AGEP). UpToDate, 2017-.

Mockenhaupt M. Introduction: Classification, Terminology, Epidemiology, and Etiology of Cutaneous Adverse Drug Reactions. In: Shear NH, Dodiuk-Gad RP (Eds.) Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends. Springer Nature Singapore Pte Ltd, Chapt.1, pp 3-23 (2018)

doi: 10.10.1007/978-981-13-1489-6_1

Mockenhaupt M, Roujeau JC. Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis). In: Kang S, Amagai M, Bruckner A, Enk AH, Margolis DJ, McMichael AJ, Orringer JS (Eds.) Fitzpatrick’s Dermatology, 9th. Edition. McGraw Hill Education, New York, Chapt 44, pp 733-748 (2019)

Roujeau JC, Mockenhaupt M. Erythema multiforme. In: Kang S, Amagai M, Bruckner A, Enk AH, Margolis DJ, McMichael AJ, Orringer JS (Eds.) Fitzpatrick’s Dermatology, 9th. Edition. McGraw Hill Education, New York, Chapt 43, pp 723-732 (2019)

Chia-Yu Chu. Acute Generalized Exanthematous Pustulosis (AGEP).Section E. Chapter 5d. Global Atlas of Skin Allergy, 2019. European Academy of Allergy and Clinical Immunology (EAACI), Zurich, Switzerland.

Maja Mockenhaupt. Cutaneous drug hypersensitivity reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN). EAACI global atlas of skin allergy, published online by the European Academy of Allergy and Clinical Immunology, pp 158-161 (2019)